AbbVie Secures NMPA Priority Review for Epcoritamab in Relapsed Follicular Lymphoma
CompanyDrug

AbbVie Secures NMPA Priority Review for Epcoritamab in Relapsed Follicular Lymphoma

Replicate Bioscience Teams With Novo Nordisk On srRNA‑Powered Metabolic Drugs
CompanyDeals

Replicate Bioscience Teams With Novo Nordisk On srRNA‑Powered Metabolic Drugs

Simcere Secures NMPA Approval for Deunoxavir Marboxil, First Pediatric Influenza Drug
CompanyDrug

Simcere Secures NMPA Approval for Deunoxavir Marboxil, First Pediatric Influenza Drug

FDA Unveils RDEP to Accelerate Rare Disease Therapy Development
Policy / Regulatory

FDA Unveils RDEP to Accelerate Rare Disease Therapy Development

Aosaikang Launches Phase III Trial of ASK202 with Leatinib for NSCLC
CompanyDrug

Aosaikang Launches Phase III Trial of ASK202 with Leatinib for NSCLC

Ab&B Bio‑Tech Wins NMPA Approval for First‑Ever Quadrivalent Influenza Subunit Vaccine
CompanyDrug

Ab&B Bio‑Tech Wins NMPA Approval for First‑Ever Quadrivalent Influenza Subunit Vaccine

Sanofi’s Tzield Earns China NMPA Approval for Stage 2 Type 1 Diabetes
CompanyDrug

Sanofi’s Tzield Earns China NMPA Approval for Stage 2 Type 1 Diabetes

Zenas Secures $300 M Royalty Deal for Obexelimab – Royalty Pharma to Invest
CompanyDeals

Zenas Secures $300 M Royalty Deal for Obexelimab – Royalty Pharma to Invest

Enlaza‑Vertex Partner on $45 M Multi‑Target Drug Discovery Collaboration
CompanyDeals

Enlaza‑Vertex Partner on $45 M Multi‑Target Drug Discovery Collaboration

Servier Secures Global Rights to Darovasertib for Uveal Melanoma Treatment
CompanyDeals

Servier Secures Global Rights to Darovasertib for Uveal Melanoma Treatment

JT118 Vaccine Receives NMPA Approval for Monkeypox Prevention
CompanyDrug

JT118 Vaccine Receives NMPA Approval for Monkeypox Prevention

Pfizer‑BioNTech Receives FDA Approval for New COVID‑19 Vaccine Indication for High‑Risk Adults
CompanyDrug

Pfizer‑BioNTech Receives FDA Approval for New COVID‑19 Vaccine Indication for High‑Risk Adults